tetano
Editor, Senior Moderator
Am J Perinatol
. 2023 Apr 18.
doi: 10.1055/s-0042-1753488. Online ahead of print.
Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019
Antonio Riccardo Buonomo[SUP] 1 [/SUP], Isabella Di Filippo[SUP] 1 [/SUP], Nunzia Esposito[SUP] 1 [/SUP], Gabriele Saccone[SUP] 2 [/SUP], Mariano Nobile[SUP] 1 [/SUP], Giulio Viceconte[SUP] 1 [/SUP], Riccardo Villari[SUP] 2 [/SUP], Costantino Di Carlo[SUP] 2 [/SUP], Giuseppe Bifulco[SUP] 2 [/SUP], Ivan Gentile[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19).
Study design: We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab.
Results: Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease.
Conclusion: Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease.
Key points: · Casirivimab/imdevimab is not well studied in pregnant women.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 decreases the risk of severe disease.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 is well tolerated..
. 2023 Apr 18.
doi: 10.1055/s-0042-1753488. Online ahead of print.
Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019
Antonio Riccardo Buonomo[SUP] 1 [/SUP], Isabella Di Filippo[SUP] 1 [/SUP], Nunzia Esposito[SUP] 1 [/SUP], Gabriele Saccone[SUP] 2 [/SUP], Mariano Nobile[SUP] 1 [/SUP], Giulio Viceconte[SUP] 1 [/SUP], Riccardo Villari[SUP] 2 [/SUP], Costantino Di Carlo[SUP] 2 [/SUP], Giuseppe Bifulco[SUP] 2 [/SUP], Ivan Gentile[SUP] 1 [/SUP]
Affiliations
- PMID: 37072016
- DOI: 10.1055/s-0042-1753488
Abstract
Objective: The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19).
Study design: We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab.
Results: Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease.
Conclusion: Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease.
Key points: · Casirivimab/imdevimab is not well studied in pregnant women.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 decreases the risk of severe disease.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 is well tolerated..